<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841880</url>
  </required_header>
  <id_info>
    <org_study_id>RAMFE_L_03420</org_study_id>
    <nct_id>NCT00841880</nct_id>
  </id_info>
  <brief_title>China Medical University Hospital (CMUH) Triapin Listing</brief_title>
  <official_title>A Prospective, Open Label, Randomized, Comparative Study of Ramipril 5mg Plus Felodipine 5mg Combined Regimen and Ramipril 10mg in Uncontrolled Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the reduction in office seated systolic blood
      pressure (BP) following a 8 weeks regimen of ramipril 5mg plus felodipine 5mg versus ramipril
      10mg.

      To compare the response rate (defined as office systolic blood pressure (SBP) / Diastolic
      blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate (defined
      as SBP&lt;140mmHg and/or DBP&lt;90mmHg) and as SBP &lt; 130 mmHg and /or DBP &lt; 80 mmHg in
      diabetes,chronic kidney disease, known Coronary Arterial Disease (CAD) or CAD equivalent, or
      10-year Framingham risk score &gt; 10%.

      To ascertain the safety and tolerability of ramipril/felodipine versus ramipril in Taiwanese
      population.

      To compare compliance with fixed dose combination of ramipril/felodipine versus ramipril
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seated SBP at office</measure>
    <time_frame>After 8-week treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seated DBP at office</measure>
    <time_frame>After 4 and 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP at office</measure>
    <time_frame>After 4-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>After 4 and 8-week treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BP controlled rate</measure>
    <time_frame>After 4 and 8-week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril + Felodipine</intervention_name>
    <description>Ramipril 5mg + Felodipine 5mg once a day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>10 mg once a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>5mg once a day</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Uncontrolled essential hypertension defined by office SBP/DBP &gt; 140/90 or &gt; 130/80
             mmHg for compelling indications (diabetes mellitus, chronic kidney disease, known CAD
             or CAD equivalent or 10-year Framingham risk score &gt; 10%)

          -  Previously untreated, or previously treated with a single antihypertensive therapy at
             usual dose during the last 4 weeks

        Exclusion criteria:

          -  Female who are pregnant or breast feeding

          -  Office DBP&gt; 110mmHg or office SBP &gt;180mmHg

          -  Hypersensitivity to ramipril, felodipine or to any of the excipients

          -  Bilateral stenosis of the renal arteries, or unilateral stenosis in the single kidney

          -  History of intolerance to any ACE inhibitor

          -  History of significant renal diseases including: serum creatinine &gt;3.0 mg/dl, or
             creatinine clearance &lt;30 ml/min

          -  History of hereditary and/or idiopathic angioedema; or angioedema associated with
             previous ACEI

          -  Significant cardiovascular diseases, multiple drug allergies, bronchospastic disease
             or other malignancies requiring current medication

          -  Hepatic disease as indicated by any of the following: Serum Glutamooxaloacetate
             Transferase (SGOT) or Serum Glutamopyruvate Transferase (SGPT)&gt;3 x upper limit of
             normal, or serum bilirubin &gt; 2 x upper limit of normal

          -  Any other condition or therapy that, in the investigator's opinion, or as indicated in
             the product(s) label may pose a risk to the patient or interfere with the study
             objective.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fern Lim</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Felodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

